2020
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers
Kim H, Nguyen N, Turner K, Wu S, Gujar A, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, Amin S, Yi E, Menghi F, Schulte J, Henssen A, Chang H, Beck C, Mischel P, Bafna V, Verhaak R. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nature Genetics 2020, 52: 891-897. PMID: 32807987, PMCID: PMC7484012, DOI: 10.1038/s41588-020-0678-2.Peer-Reviewed Original ResearchConceptsOncogene amplificationPoor outcomeCancer typesEcDNA amplificationShorter survivalCancer patientsMost cancer typesExtrachromosomal DNA amplificationsClinical impactMultiple cancersPatientsNormal tissuesCancerTranscript fusionsEnhanced chromatin accessibilityIntratumoral genetic heterogeneityOncogene transcriptionChromosomal amplificationOutcomesGenetic heterogeneityHigh levelsDNA amplificationTissue typesBlood
2019
Longitudinal molecular trajectories of diffuse glioma in adults
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 2019, 576: 112-120. PMID: 31748746, PMCID: PMC6897368, DOI: 10.1038/s41586-019-1775-1.Peer-Reviewed Original ResearchConceptsAdult patientsDiffuse gliomasRecurrent gliomaOverall survivalPoor outcomeCurrent therapiesChromosome arms 1p/19qAcquired alterationsMajor subtypesTherapeutic resistanceGliomasGlioma developmentGene alterationsIDH mutationsGlioma subtypesPatientsHypermutator phenotypeDriver genesSubtypesClinical annotationSurvivalSubclonal selectionCell cycleAlterationsLittle evidenceThe effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma
Adamia S, Abiatari I, Amin S, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi N, Anderson K. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia 2019, 34: 167-179. PMID: 31182781, PMCID: PMC6901818, DOI: 10.1038/s41375-019-0498-5.Peer-Reviewed Original ResearchConceptsMultiple myelomaPlasma cellsOvert multiple myelomaPatient outcomesMM cellsMM pathogenesisLet-7fMicroRNA deregulationRegulation of microRNAsCD138Certain miRsMyelomaMiRDependent gene expressionDeregulated expressionMiR-mediated regulationSignificant numberEpigenetic lesionsTarget genesMM genomesExpressionGene expressionEarly stagesCellsPatients
2010
Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma
Mahindra A, Amin S, Sohani A, Motyckova G, Patel K, Vallet S, Pozzi S, Santo L, Cirstea D, Toomey C, Michaelson J, Hochberg E, Dal Cin P, Rodig S, Hideshima T, Anderson K, Munshi N, Raje N. Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. Blood 2010, 116: 4042. DOI: 10.1182/blood.v116.21.4042.4042.Peer-Reviewed Original ResearchMultiple myelomaMedullary plasmacytomaTissue microarrayMean overall survivalRisk of progressionPlasma cell disordersNew therapeutic approachesOverall survivalMale preponderanceMedian ageSolitary lesionMultiple lesionsPathological diagnosisPtch-1Plasma cellsTherapeutic approachesCell myelomaCell disordersPatientsSolid tumorsClonal proliferationMetastatic potentialPlasmacytomaMyelomaMolecular profiling